April 13, 2021

TFF Pharmaceuticals Awarded Contract under DARPA’s Next-Generation Personalized Protective Biosystems Program for U.S. Warfighters

March 26, 2021

TFF Pharmaceuticals Prices Offering of Common Stock

March 10, 2021

TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Business Results

March 9, 2021

NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration

March 9, 2021

Feasibility Arrangement for Shelf-stable Powder Form of Messenger RNA COVID-19 Vaccine Candidate Announced by GreenLight Biosciences and TFF Pharmaceuticals

March 5, 2021

TFF Pharmaceuticals to Present at Virtual Investor Conferences in March 2021

March 4, 2021

TFF Pharmaceuticals Provides Update on Clinical Development Programs

February 24, 2021

TFF Pharmaceuticals to Hold Fourth Quarter and Full-Year 2020 Financial Results and Business Results Conference Call on March 10, 2021

February 19, 2021

TFF Pharmaceuticals Announces Positive Preclinical Results with Two Biodefense Countermeasures for the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)

February 12, 2021

TFF Pharmaceuticals to Present at the BIO CEO & Investor Digital Conference